EGFR and cancer: Furthermore, colon cancer patients who responded (n = 19) to antibody‐based EGFR inhibition therapy (cetuximab) had significantly higher cancer tissue expression of ECAD (IHC scoring) than patients not responding (n = 17) [49] to treatment.